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Background. Persistent infection with high-risk human papillomavirus (HR-HPV) has been demonstrated to be the necessary
causal factor for developing cervical cancer. To know the most prevalent HR-HPV in diﬀerent geographical areas is important
to design diagnostic tests and implementation of vaccines. Objectives. The goal of this study is to evaluate the prevalence of HR-
HPV in a total of 1001 patients, 198 with normal cytology results, 498 with low-grade squamous intraepithelial lesion (LSIL),
and 205 with high-grade squamous intraepithelial lesion (HSIL) who attended our gynaecology department for opportunistic
screening of HPV infection. Study design. Cervical samples were taken in a PreservCyt vial (Cytyc Corporation, Boxborough, MA).
Hybrid capture assay was carried out following the manufacturer’s instructions (Digene Corp., Gaithersburg, MD). All samples
were further studied with polymerase chain reaction (PCR) (Linear Array HPV Genotyping Test, Roche Diagnostics, Mannheim,
Germany). Results. Genotype 16 was the most prevalent HR-HPV in the three groups, 17.8% in the patients with normal cytology
results,22.3%intheLSILgroup,and60%intheHSILgroup.Genotype18hadaverylowprevalenceinallgroups.OtherHR-HPV
genotypes such as genotype 31, genotype 58 and genotype 52 were found in signiﬁcant numbers in HSIL patients. Discussion.O u r
data show that genotypes 16, 31, 58, and 52 are the most prevalent HR-HPV in cervical samples with severe intraepithelial lesion
in Spain. There may be some geographical variation in prevalence of carcinogenic types, and it must be considered for designing
diagnostic tests and vaccine.
1.Background
Persistent infection with some genotypes of human papil-
lomavirus (HPV) is the cause of cervical cancer. This virus
comprises more than 100 genotypes of which 12 have been
recognized as clearly oncogenic viruses and deﬁned as “high
risk-genotypes” (HR-HPV) (16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, and 59). In addition, six more genotypes have been
deﬁned as “probably high risk” (26, 53, 66, 68, 73, and 82)
[1]. There is increasing evidence that some HR-HPVs are
more carcinogenic than others, particularly genotypes 16,
18, and 45 [2], and therefore, some authors have suggested
that women older than 30 years with negative cytological
results and infected with genotype 16 or 18 must be referred
for colposcopy [3]. Consequently, the speciﬁc HR-HPV
genotype detected is an important indicator of the risk for
developing high-grade squamous intraepithelial lesion or
greater (HSIL).
For these reasons and considering that HPV immunity
is genotype speciﬁc, it is important to deﬁne HR-HPV
prevalence in diﬀerent geographical regions. To our knowl-
edge there are limited data concerning the distribution of2 Advances in Preventive Medicine
HR-HPV in Spanish women with precancerous or >HSIL
lesions.
2.Objectives
This study aimed to deﬁne HR-HPV genotypes present in
women with histological conﬁrmed HSIL in comparison
with HR-HPV genotypes present in women with mild cer-
vical lesions or low-grade squamous intra-epithelial lesion
(LSIL). Another goal of our study was to investigate whether
genotypes 16 and 18 are the most prevalent in women with
histological abnormalities in order to ascertain the beneﬁts
of vaccine implementation in our country and choice of
diagnostic tests.
3. Study Design
3.1. Patients. From April 2006 to April 2009, 1001 con-
secutive women attending the Gynaecologic Department of
Ram´ on y Cajal Hospital (Madrid, Spain) were prospectively
included in this study. All the patients underwent a cervical
swab for cytology and HPV detection taken on the initial
visit to the gynaecology consultation. Only women with
positive hybrid capture assay (HC2) results and available
cytology results conﬁrmed with histology were included in
the study. If both results were discordant, histological results
were considered. Results were recorded following the 2001
Bethesda System terminology [4].
3.2. Methods. Cervical samples were taken and washed in a
Preservcyt vial (Cytyc Corporation, Boxborough, MA) and
sent to the Virology Unit of Ram´ on y Cajal Hospital for
HPV detection. HC2 assay was carried out following the
manufacturer’s instructions after using a sample conversion
kit (Digene Corp., Gaithersburg, MD). The samples were
examined for the presence of HR-HPV types 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, and 68. Positive and negative
controls were included in each run.
All positive samples were further studied with poly-
merasechainreaction(PCR)(LinearArrayHPVGenotyping
Test,Roche Diagnostics, Mannheim,Germany).DNA extrac-
tion was performed automatically with a method validated
previously in [5]. The primer pair PGMY09/11 included in
this test is designed to detect 37 genotypes including 13
HR-HPVs (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51,
52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70,
71, 72, 73, 81, 82, 83, 84, CP6108, and IS39). The human
beta-globin gene is ampliﬁed as internal control. After the
hybridization reaction, the strips were read visually with a
reference guide.
3.3. Statistical Methods. Summary statistics (n, mean, stan-
dard error, median, min, max) for age at study entry by
cytological and histological results were produced (Table 1).
Patients with cervical intraepithelial neoplasia grade 3
(CIN3)resultswerelateranalyzedseparatelyforamoreaccu-
rate interpretation of the data. Mean age among cytological
and histological results was compared using the Kruskal-
Wallis test. Prevalence of HR-HPV types by cytological and
histological results (normal, LSIL, HSIL, and CIN3) was
computed irrespective of the presence of mixed infections
(more than one HR-HPV genotype) (Table 2).
4. Results
We found 298 women with normal cytology, 498 with LSIL,
and 205 with HSIL. CIN 3 was recorded in 111/205 patients
from the HSIL group (Table 2), and these samples were
studied separately since they represent the real target of
cervical cancer screening campaigns.
As shown in Table 2, the most prevalent HR-HPV types
in patients with normal cytology were HPV-16 (17.8%)
followed by HPV-31 (12.8%) and HPV-52 (12.4%). In total,
17 HR-HPV types were represented. In the LSIL group
of patients, the most prevalent HR-HPV types were HPV-
16 (22.3%), HPV-53 (15.9%), and HPV-51 (14.1%). In
women with HSIL cytological results the most prevalent HR-
HPV types found were HPV-16 (60%), HPV-31 (15.1%),
and HPV-58 (12.2%). If only patients with CIN3 lesions
were selected, the predominant genotypes were the same
with slight diﬀerences, HPV-16 (64%) followed by HPV-31
(14%), and HPV-58 (11.4%). Genotypes 16, 31 and 58 were
more prevalent in CIN3 (64%, 14%, and 11.4%. resp.) than
in LSIL patients ( 22.3%, 12.7%, and 8.2%, resp.) although
the diﬀerence was only statistically signiﬁcant for genotype
16 (CIN3:LSIL prevalence ratio: 8.43, 95% CI: 5.41–13.13
for genotype 16, CIN3:LSIL prevalence ratio 1.16, 95% CI:
0.64–2.10 for genotype 31 and CIN3:LSIL prevalence ratio
1.48 95% CI: 0.76–2.86 for genotype 58). Genotypes 16 or 18
were not present in 33 patients (29%) and the most frequent
HR-HPV genotypes in these patients were 31, 58, 33 and 52
(10%, 10%, 7% and 5%, resp.). Only one LR-HPV, genotype
84, was found as a single type in only one CIN3 patient. The
average age of women with LSIL and HSIL was 35.3 and 39.1
years, respectively (Table 1). This diﬀerence is statistically
signiﬁcant (P<. 0001) age.
5. Discussion
Ourcross-sectionalstudywasperformedonpatientsreferred
to the gynaecology oﬃce seeking for an opportunistic
cervical cancer screening. Although these results cannot
be extrapolated to a population-based screening, some
interesting data were found. To establish the prevalence
and distribution of HR-HPV in diﬀerent geographical areas
is very important in order to predict the beneﬁts of
vaccination and to design cancer screening programs with
diagnostic tests including the most prevalent genotypes in
each geographical area. Smith et al. [6]h a v ep e r f o r m e da
meta-analysis study and reported that genotypes 16, 18, 31,
33, 35, 45, 52, and 58 are the most prevalent types detected
in a total of 14 595 invasive cervical cancer and 7 094 HSIL
cases. However their relative importance diﬀered in several
countries in women with CIN3 lesions. In general, HR-HPV
16and18areconsideredthetwomostprevalentgenotypesinAdvances in Preventive Medicine 3
Table 1: Summary statistics for age by histological results.
Histologya N (%) Mean ±SE Median Min Max
Normal 298 (29.8%) 36.5 ±0.73 41 6 7 9
LSILb 498 (49.7%) 35.3 ±0.53 31 6 7 7
HSILc 205 (20.5%) 39.1 ±0.83 71 8 8 2
aKruskal-Wallis test, P<. 0001.
bLow squamous intraepithelial lesion.
cHigh squamous intraepithelial lesion.
Table 2: Distribution of HR-HPV types by histological and cytological diagnosis.
HPV type
NORMAL
(n = 298) N
(%)
LSILa (n = 498)
N (%)
HSILb (n = 205)
N (%)
CIN3c




HPV-16 53 (17.8%) 111 (22.3%) 123 (60%) 73 (64%) 287 (28.7%)
HPV-18 21 (7%) 26 (5.2%) 11 (2.4%) 7 (6.1%) 58 (5.8%)
HPV-26 0 (0%) 8 (1.6%) 0 (0%) 0 (0%) 8 (0.8%)
HPV-31 38 (12.8%) 63 (12.7%) 31 (15.1%) 16 (14%) 132 (13.2%)
HPV-33 18 (6%) 41 (8.2%) 16 (7.8%) 7 (6.1%) 75 (7.5%)
HPV-35 10 (3.4%) 21 (4.2%) 6 (2.9%) 4 (3.5%) 37 (3.7%)
HPV-39 18 (6%) 39 (7.8%) 7 (3.4%) 2 (1.8%) 64 (6.4%)
HPV-45 11 (3.7%) 26 (5.2%) 6 (2.9%) 3 (2.6%) 43 (4.3%)
HPV-51 29 (9.7%) 72 (14.5%) 9 (4.4%) 3 (2.6%) 110 (11%)
HPV-52 37 (12.4%) 52 (10.4%) 19 (9.3%) 9 (7.9%) 108 (10.8%)
HPV-53 30 (10.1%) 79 (15.9%) 11 (5.4%) 3 (2.6%) 120 (12%)
HPV-56 23 (7.7%) 56 (11.2%) 10 (4.9%) 4 (3.5%) 89 (8.9%)
HPV-58 19 (6.4%) 41 (8.2%) 25 (12.2%) 13 (11.4%) 85 (8.5%)
HPV-59 14 (4.7%) 41 (8.2%) 7 (3.4%) 3 (2.6%) 62 (6.2%)
HPV-66 23 (7.7%) 61 (12.2%) 5 (2.4%) 2 (1.8%) 89 (8.9%)
HPV-68 7 (2.3%) 19 (3.8%) 3 (1.5%) 0 (0%) 29 (2.9%)
HPV-73 12 (4%) 29 (5.8%) 5 (2.4%) 1 (0.9%) 46 (4.6%)
HPV-82 3 (1%) 6 (1.2%) 3 (1.5%) 1 (0.9%) 12 (1.2%)
aLow squamous intraepithelial lesion in cytology.
bHigh squamous intraepithelial lesion in cytology.
cCervical intraepithelial neoplasia of grade 3 or worse in histology.
patientswithCIN3lesionsormoresevere.Ontheotherhand
recent reports have shown worldwide geographical variation
in the prevalence patterns of HR-HPV specially genotype 18.
For instance, in Italy, the predominant HR-HPV types are
genotypes 16 (71%), 31 (10%), and 51 (9%). Genotype 18
was only found in 6% of the patients [7]. In contrast, in
Australia, 18.3% of biopsies from women with severe lesions
contained genotype 18 [8]. In our study, using the same
primersforthePCRassay(PGMY09/11)asinthisAustralian
study,genotype18wasonlyfoundin7(6.1%)ofthepatients
with >CIN3. This genotype is also uncommon in China [9].
Interestingly, genotype 31, the second most prevalent in our
study, is also very frequent in Italy [7] and in the United
States [10] but not in other countries [8].
The failure to detect exclusively low-risk genotypes in
high-gradedysplasiashasbeenreportedbyotherauthors[8].
We found only one patient with CIN3 associated to the LR-
HPV genotype 84.
As expected the mean age of patients with HSIL is higher
than the mean age of patients with LSIL.
In conclusion, geographical variation in prevalence of
HR-HPV exits and is an important factor to consider in the
implementation of vaccine campaigns and design of new
diagnostic assays. Our study describes the HR-HPV distribu-
tion in 1001 infected women with available cytological and
histological results in Madrid, Spain. Regarding the group
of patients who developed CIN3 lesions, our data show that
genotype 16 is the most prevalent in our country but other
HR-HPVs such as genotypes 31, 58, 33, and 52 must also
be targeted in the design of diagnostic tests and prophylactic
vaccines. More information about prevalence of HR-HPV in
diﬀerent areas of the world is needed to predict how HPV4 Advances in Preventive Medicine
vaccine and the screening with an HPV test will inﬂuence
cervical cancer prevention.
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